Incyte Wins FDA Approval for Rare Bone Disease Drug
WILMINGTON, DE — Incyte (Nasdaq: INCY) won U.S. approval for zilurgisertib, a treatment it developed for fibrodysplasia ossificans progressiva, giving the company a regulatory milestone and a transferable priority-review voucher …
Incyte Wins FDA Approval for Rare Bone Disease Drug Read More